Patent intelligence · US
US 11834441
Substituted tetrahydrofurans as modulators of sodium channels
Substituted tetrahydrofurans as modulators of sodium channels
Patent details — US 11834441
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2023
- Expiration
- Nov 30, 2043
- Applicant
- Vertex Pharmaceuticals Incorporated
- Claims
- 62
- CPC classes
- A61P, A61P29/00
Quick answer
US 11834441 (Substituted tetrahydrofurans as modulators of sodium channels) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Expiration
- Claims
- 62
- CPC classes
- A61P, A61P29/00
More from Vertex Pharmaceuticals Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12421251
Cystic fibrosis transmembrane conductance regulator modulating agents
granted -
US 12421249
Inhibitors of APOL1 and methods of using same
granted -
US 12384790
Pteridinone compounds and uses thereof
granted -
US 12384762
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted -
US 12385013
Differentiation of pancreatic endocrine cells
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12371665
Differentiation of pancreatic endocrine cells
granted -
US 12350262
Methods of treatment for cystic fibrosis
granted
Related coverage
Lilly buys 4E in non-opioid pain push: what investors should watch
Eli Lilly is buying 4E Therapeutics, adding another non-opioid pain pipeline to its portfolio after the SiteOne transaction. The move comes as Journavx (suzetrigine) advances in the market and in multiple clinical trials.
FDA approves Vertex’s Journavx as first non-opioid pain drug for acute pain
The FDA approved Vertex Pharmaceuticals’ Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults. The decision creates a new non-opioid catalyst to track for BD teams, investors, and analysts.
FDA Approves Vertex’s First-in-Class Non-Opioid Pain Drug Journavx
The FDA approved Journavx (suzetrigine) on 30 January 2025 for moderate-to-severe acute pain in adults, including postoperative pain. The decision gives Vertex the first non-opioid analgesic in this setting and creates a new catalyst set for BD teams, investors, and analysts.
Vertex launches Journavx after FDA approval for acute pain
Vertex’s Journavx (suzetrigine) became the first FDA-approved non-opioid analgesic for moderate to severe acute pain on January 30, 2025. This plan frames the catalyst, label, and upcoming clinical milestones for BD teams, investors, and analysts.
Frequently asked questions
What is US patent 11834441?
US 11834441 (Substituted tetrahydrofurans as modulators of sodium channels) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11834441?
Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.
When does US 11834441 expire?
Our index shows an expiration date of Nov 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.